Personalised cancer vaccine expected to be approved next year

A vaccine built for one patient's tumor, approved as a product. The regulators will have to decide what a batch size of one even means.

A bespoke vaccine that is tailored to target an individual's unique skin cancer reduced rates of recurrence or death in a late-stage trial, making an approval expected